Founded Year



Biz Plan Competition | Alive

Total Raised


Mosaic Score

+10 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Imagia Canexia Health

Imagia Canexia Health enables collaborative AI by providing outcome-based structured clinical data and federated learning capabilities across multiple sources and researchers. Imagia's Evidens Platform uses routine clinical patient data, designed to deliver care, into outcome-based structured information appropriate for AI biomarker discovery. Imagia Healthcare delivers AI clinical solutions to B2B partners, as R&D tools, digital health products, or fully regulated software-as-medical-devices validated through the ISO13485 MDSAP certified quality system.

Imagia Canexia Health Headquarter Location

6650 Saint-Urbain Suite 100

Montreal, Quebec, H2S 3G9,



Imagia Canexia Health's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Imagia Canexia Health's Products & Differentiation

See Imagia Canexia Health's products and how their products differentiate from alternatives and competitors

  • Find It (Tissue)

    Tissue based test for treatment selection

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Imagia Canexia Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Imagia Canexia Health in 2 CB Insights research briefs, most recently on Jan 13, 2020.

Expert Collections containing Imagia Canexia Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Imagia Canexia Health is included in 4 Expert Collections, including Digital Health.


Digital Health

12,910 items

Startups recreating how healthcare is delivered


Artificial Intelligence

8,693 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

7,910 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Imagia Canexia Health Patents

Imagia Canexia Health has filed 4 patents.

The 3 most popular patent topics include:

  • Image processing
  • Artificial neural networks
  • Association football record progressions
patents chart

Application Date

Grant Date


Related Topics




Machine learning, Artificial neural networks, Medical imaging, Classification algorithms, Image processing


Application Date


Grant Date



Related Topics

Machine learning, Artificial neural networks, Medical imaging, Classification algorithms, Image processing



Latest Imagia Canexia Health News

09:00 EDT Digital Technology Supercluster Announces Investment to Increase the Effectiveness of Precision Oncology

Apr 21, 2022

News provided by Share this article Share this article Harnessing artificial intelligence to take the guesswork out of diagnosing cancer recurrence for millions of cancer survivors VANCOUVER, BC, April 21, 2022 /CNW/ - Canada's Digital Technology Supercluster is excited to be investing in AI and technology innovation that will advance personalized cancer treatment and improve patient outcomes. Led by Imagia Canexia Health, in partnership with BC Cancer Research, DNAstack, Microsoft, Queen's University and University Health Network, the CanDETECT project is developing a precision oncology software that will monitor cancer recovery and recurrence for millions of Canadian cancer survivors. "Digital healthcare innovations can have a significant positive impact for cancer patients and their families," said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. "By detecting relapse or resistance to therapy early, the CanDETECT project can help improve patient outcomes, reduce cancer care backlogs and build greater resiliency across Canada's healthcare systems. This is one more example of how the Digital Technology Supercluster and digital innovation can help Canadians and their families during very difficult times." Cancer remains the leading cause of death in Canada, and according to Canadian Cancer Society nearly half of Canadians are expected to receive a diagnosis of cancer in their lifetime. The recovery of cancer patients and survivors depends on close monitoring of treatment response and ensuring recurrence is detected early. However, current approaches are largely ad-hoc, costly and have a low success rate, providing generic data on the presence of cancer with no specific treatment guidance. The current 'one size fits all' approach limits the chance of effective treatment and survival. "The AI-based oncology software being developed and tested as a part of the CanDETECT project will enable clinicians to perform a real-time assessment of tumor status, detect earlier signs of patient relapse and recommend alternative treatment options, ensuring the best possible outcome faster, more accurately and at less cost than current solutions," said Geralyn Ochab, CEO of Imagia Canexia Health. "This 'Made in Canada' solution will transform cancer care for Canadians." The AI-based oncology software will identify and predict the best available targeted therapies and/or clinical trials for cancer patients throughout the course of their treatment and will analyze and track how each patient responds to therapy over time. The consortium will also harness artificial intelligence, machine learning and big data to better predict patient response to targeted therapy by integrating and analyzing multimodal patient data. "The ability to monitor cancer recurrence dynamically means we can offer patients personalized treatment responsive to the changing biology of their cancer," said Bill Tam, COO of the Digital Technology Supercluster. "We are extremely proud of the break-through research and development happening between Imagia Canexia Health, BC Cancer Research, DNAstack, Microsoft, Queen's University and University Health Network. Together we are accelerating progress against cancer and improving survival outcomes for all Canadians." The CanDETECT project has a total investment of $17.8 million, with $12.5 million invested by industry and $5.3 million co-invested through the Supercluster's Technology Leadership program. Other supporting partners involved in this project include Illumina, Kingston General Health Research Institute and Kingston Health Sciences Centre. More information on CanDETECT can be found here . About Canada's Digital Technology Supercluster Ahead of the curve starts here. The Digital Supercluster drives digital innovation that is the foundation of a resilient Canadian economy. We impact the lives of all Canadians through technology advancements that prioritize environmental sustainability, advance healthcare and accelerate business transformation and growth. Through a powerful combination of multi-sector collaboration, industry co-investment, IP creation and digitally skilled talent development, the Digital Supercluster is helping Canada fight against the pandemic, leverage 'green' technologies to power the economy and improve the health and safety of every Canadian now, and for generations to follow. Learn more at: SOURCE Digital Technology Supercluster For further information: Media Contact: Elysa Darling, Director, Government Relations & Public Affairs, Canada's Digital Technology Supercluster, Email: [email protected] , Phone: 587-890-9833 ×

Imagia Canexia Health Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Imagia Canexia Health Rank

You May Also Like

Holmusk Logo

Holmusk is a data science and digital therapeutics company with a global presence that is dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Holmusk's proprietary technology powers data-driven medicine that leverages analytic and digital tools to address the unmet need in healthcare and pharma-life science.

nference Logo

nference offers a platform that enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference makes biomedical knowledge computable and builds its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

Evidation Logo

Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.

Syapse Logo

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying next-generation sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations.

Owkin Logo

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.

Strata Oncology Logo
Strata Oncology

Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.